The U.S. Court of Appeals for the Federal Circuit remanded a patent infringement dispute involving Guardant Health, TwinStrand Biosciences, and the University of Washington back to the Patent Trial and Appeal Board (PTAB). The case concerns duplex consensus sequencing methods and previously resulted in a jury award against Guardant that included royalties and damages. The appeals court asked the PTAB to reconsider the validity of one patent under a different legal framework, potentially improving Guardant’s position. The decision leaves open exposure related to a second patent and possible trebled damages for willful infringement, but it introduces a pathway that could reduce or overturn parts of the original ruling.